Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q1 2025 Earnings Report

BioVie logo
$2.03 0.00 (0.00%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

BioVie EPS Results

Actual EPS
-$4.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q1 2025
Date
2/11/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BioVie's Q1 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q1 2025 Quarterly reportQuarterly report
(10-Q)

BioVie Earnings Headlines

BioVie Inc. (NASDAQ:BIVI) Short Interest Up 56.7% in August
September 1 at 1:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30995355
BioVie completes final patient visit in Phase 2 Long COVID trial
August 31 at 9:24 AM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1097845?snapi
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
September 3 at 1:00 AM  |  Porter & Company (Ad)
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
August 31 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353257/0/en/biovie-announces-completion-of-treatment-phase-of-address-lc-trial-of-bezisterim-for-the-treatment-of-neurological-symptoms-associated-with-long-covid.html
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935669-biovie-inc-bivi-discusses-bezisterim-mechanism-of-action-and-sunrise-pd-phase-ii-trial-design
Why BioVie (BIVI) Stock Is Up Today
August 12, 2026  |  quiverquant.comQ
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit.

In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices.

Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.

View BioVie Profile
Earnings Tools